| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Macrophage Activation Syndrome | 9 | 2020 | 342 | 4.15 | Why? |
| Still's Disease, Adult-Onset | 7 | 2020 | 100 | 3.66 | Why? |
| Arthritis, Rheumatoid | 18 | 2021 | 2043 | 3.44 | Why? |
| Scleroderma, Systemic | 9 | 2019 | 583 | 3.00 | Why? |
| Sjogren's Syndrome | 11 | 2019 | 284 | 2.36 | Why? |
| Myofibroblasts | 2 | 2019 | 61 | 1.51 | Why? |
| Adipokines | 2 | 2019 | 87 | 1.43 | Why? |
| Autoimmune Diseases | 7 | 2020 | 1996 | 1.29 | Why? |
| Ferritins | 5 | 2020 | 2055 | 1.11 | Why? |
| Interleukin-1 | 2 | 2019 | 438 | 1.09 | Why? |
| Rheumatic Diseases | 5 | 2019 | 2675 | 0.99 | Why? |
| Tumor Necrosis Factor-alpha | 5 | 2019 | 2483 | 0.97 | Why? |
| Antirheumatic Agents | 6 | 2019 | 3023 | 0.89 | Why? |
| Salivary Glands | 3 | 2018 | 122 | 0.85 | Why? |
| Iron Metabolism Disorders | 1 | 2020 | 24 | 0.84 | Why? |
| Interleukin 1 Receptor Antagonist Protein | 3 | 2019 | 1165 | 0.82 | Why? |
| Methotrexate | 4 | 2019 | 471 | 0.81 | Why? |
| Arthritis, Juvenile | 2 | 2020 | 191 | 0.74 | Why? |
| Raynaud Disease | 1 | 2019 | 86 | 0.73 | Why? |
| Macrophage Activation | 2 | 2017 | 315 | 0.73 | Why? |
| Cell Differentiation | 4 | 2019 | 1338 | 0.73 | Why? |
| Apoferritins | 1 | 2017 | 32 | 0.73 | Why? |
| Inflammation Mediators | 3 | 2018 | 2654 | 0.72 | Why? |
| Arthritis | 2 | 2021 | 288 | 0.71 | Why? |
| Autoimmunity | 4 | 2020 | 841 | 0.67 | Why? |
| Cardiovascular Diseases | 7 | 2018 | 11497 | 0.67 | Why? |
| Macrophages | 3 | 2019 | 2784 | 0.65 | Why? |
| Antigens, Neoplasm | 1 | 2018 | 230 | 0.65 | Why? |
| Extracellular Matrix | 1 | 2018 | 189 | 0.64 | Why? |
| Receptors, Interleukin-1 | 1 | 2018 | 161 | 0.63 | Why? |
| T-Lymphocytes, Regulatory | 2 | 2019 | 698 | 0.62 | Why? |
| Antigens, CD | 2 | 2018 | 984 | 0.61 | Why? |
| Glucose Intolerance | 1 | 2017 | 115 | 0.61 | Why? |
| Hepatitis E virus | 1 | 2019 | 306 | 0.59 | Why? |
| Coronary Circulation | 1 | 2017 | 188 | 0.59 | Why? |
| Diabetes Mellitus, Type 2 | 6 | 2019 | 6166 | 0.57 | Why? |
| Hepatitis E | 1 | 2019 | 319 | 0.56 | Why? |
| Myocardial Perfusion Imaging | 1 | 2017 | 218 | 0.56 | Why? |
| Atherosclerosis | 3 | 2018 | 768 | 0.56 | Why? |
| Cell Proliferation | 3 | 2018 | 1973 | 0.55 | Why? |
| Bone Marrow | 1 | 2017 | 492 | 0.54 | Why? |
| Neovascularization, Pathologic | 1 | 2018 | 305 | 0.54 | Why? |
| Vasodilator Agents | 1 | 2017 | 344 | 0.53 | Why? |
| Insulin Resistance | 2 | 2019 | 669 | 0.53 | Why? |
| Multidetector Computed Tomography | 1 | 2017 | 307 | 0.52 | Why? |
| Blood Proteins | 1 | 2017 | 551 | 0.52 | Why? |
| Adenosine | 1 | 2017 | 509 | 0.50 | Why? |
| Microcirculation | 1 | 2017 | 447 | 0.50 | Why? |
| Metabolic Diseases | 1 | 2018 | 505 | 0.49 | Why? |
| Immunosuppressive Agents | 4 | 2019 | 6331 | 0.49 | Why? |
| Evidence-Based Practice | 1 | 2018 | 693 | 0.48 | Why? |
| Interleukin-1beta | 1 | 2018 | 992 | 0.48 | Why? |
| Magnetic Resonance Imaging, Cine | 1 | 2017 | 669 | 0.47 | Why? |
| Inflammation | 6 | 2020 | 13255 | 0.46 | Why? |
| Musculoskeletal Diseases | 1 | 2019 | 646 | 0.43 | Why? |
| Fibrosis | 3 | 2019 | 800 | 0.42 | Why? |
| Mucocutaneous Lymph Node Syndrome | 1 | 2020 | 1645 | 0.37 | Why? |
| Fibromyalgia | 2 | 2021 | 174 | 0.34 | Why? |
| Biomarkers | 5 | 2018 | 23361 | 0.34 | Why? |
| Adrenal Cortex Hormones | 3 | 2019 | 6537 | 0.33 | Why? |
| Biological Products | 3 | 2019 | 2331 | 0.32 | Why? |
| Cytokines | 6 | 2020 | 15010 | 0.32 | Why? |
| Immunotherapy | 1 | 2020 | 2421 | 0.31 | Why? |
| Syndrome | 3 | 2021 | 1310 | 0.30 | Why? |
| Lung Diseases, Interstitial | 1 | 2017 | 1476 | 0.30 | Why? |
| Humans | 72 | 2021 | 930598 | 0.29 | Why? |
| Remission Induction | 2 | 2019 | 950 | 0.29 | Why? |
| Interleukin-6 | 2 | 2020 | 7522 | 0.28 | Why? |
| Early Diagnosis | 3 | 2018 | 2443 | 0.27 | Why? |
| Antibodies, Monoclonal, Humanized | 4 | 2020 | 9335 | 0.25 | Why? |
| Arthritis, Psoriatic | 2 | 2019 | 625 | 0.25 | Why? |
| Adipose Tissue | 2 | 2019 | 612 | 0.24 | Why? |
| Hypotrichosis | 1 | 2020 | 40 | 0.21 | Why? |
| Biopsy | 3 | 2018 | 2811 | 0.21 | Why? |
| Adult | 28 | 2021 | 244371 | 0.21 | Why? |
| Systemic Inflammatory Response Syndrome | 1 | 2020 | 6653 | 0.21 | Why? |
| Middle Aged | 29 | 2021 | 270681 | 0.20 | Why? |
| Skin Diseases, Genetic | 1 | 2020 | 65 | 0.20 | Why? |
| Heart Diseases | 1 | 2017 | 3503 | 0.20 | Why? |
| Pathogen-Associated Molecular Pattern Molecules | 1 | 2020 | 108 | 0.20 | Why? |
| Certolizumab Pegol | 1 | 2019 | 36 | 0.20 | Why? |
| Receptors, Interleukin-17 | 1 | 2018 | 9 | 0.19 | Why? |
| Dose-Response Relationship, Drug | 2 | 2019 | 3776 | 0.19 | Why? |
| Mononuclear Phagocyte System | 1 | 2018 | 31 | 0.19 | Why? |
| Pericytes | 1 | 2019 | 108 | 0.18 | Why? |
| Cryoglobulins | 1 | 2018 | 51 | 0.18 | Why? |
| Complement C4 | 1 | 2018 | 86 | 0.18 | Why? |
| Protein Tyrosine Phosphatases | 1 | 2017 | 12 | 0.18 | Why? |
| Transforming Growth Factor beta | 2 | 2017 | 363 | 0.18 | Why? |
| Autoimmune Diseases of the Nervous System | 1 | 2019 | 141 | 0.18 | Why? |
| Interleukin-9 | 1 | 2017 | 29 | 0.18 | Why? |
| Tomography, X-Ray Computed | 3 | 2020 | 25144 | 0.18 | Why? |
| Stromal Cells | 1 | 2018 | 105 | 0.18 | Why? |
| Immediate-Early Proteins | 1 | 2017 | 44 | 0.18 | Why? |
| Phosphopeptides | 1 | 2017 | 18 | 0.18 | Why? |
| Antiphospholipid Syndrome | 2 | 2020 | 533 | 0.18 | Why? |
| Male | 31 | 2021 | 367725 | 0.18 | Why? |
| Female | 33 | 2021 | 380317 | 0.17 | Why? |
| Antibodies, Monoclonal | 1 | 2017 | 8041 | 0.17 | Why? |
| Biomarkers, Pharmacological | 1 | 2018 | 150 | 0.17 | Why? |
| Molecular Targeted Therapy | 2 | 2017 | 1579 | 0.17 | Why? |
| Antibodies, Fungal | 1 | 2017 | 49 | 0.17 | Why? |
| Lymphoma, B-Cell, Marginal Zone | 1 | 2017 | 44 | 0.17 | Why? |
| Sclerosis | 1 | 2017 | 26 | 0.17 | Why? |
| Immunity, Innate | 4 | 2020 | 6570 | 0.17 | Why? |
| Treatment Outcome | 8 | 2019 | 51732 | 0.17 | Why? |
| Lipoproteins, LDL | 1 | 2018 | 115 | 0.17 | Why? |
| Calcinosis | 1 | 2020 | 240 | 0.17 | Why? |
| C-Reactive Protein | 3 | 2018 | 7972 | 0.16 | Why? |
| Pleural Diseases | 1 | 2017 | 68 | 0.16 | Why? |
| Epithelial-Mesenchymal Transition | 1 | 2019 | 242 | 0.16 | Why? |
| Immune System Diseases | 1 | 2021 | 410 | 0.16 | Why? |
| Antigens, Differentiation, Myelomonocytic | 1 | 2017 | 198 | 0.16 | Why? |
| Lymphoid Tissue | 1 | 2017 | 162 | 0.16 | Why? |
| Lupus Erythematosus, Systemic | 2 | 2018 | 1380 | 0.16 | Why? |
| Age of Onset | 1 | 2018 | 557 | 0.16 | Why? |
| Amyloidosis | 1 | 2018 | 178 | 0.16 | Why? |
| Blood Sedimentation | 1 | 2018 | 508 | 0.16 | Why? |
| Cholesterol | 2 | 2017 | 660 | 0.16 | Why? |
| Prognosis | 6 | 2020 | 32490 | 0.15 | Why? |
| Spondylitis, Ankylosing | 1 | 2018 | 231 | 0.15 | Why? |
| Mannans | 1 | 2017 | 218 | 0.15 | Why? |
| Spinal Cord Injuries | 1 | 2020 | 270 | 0.15 | Why? |
| Adiposity | 1 | 2019 | 329 | 0.15 | Why? |
| Complement C3 | 1 | 2018 | 271 | 0.15 | Why? |
| Heart Valve Diseases | 1 | 2020 | 355 | 0.15 | Why? |
| Benzamides | 1 | 2018 | 421 | 0.15 | Why? |
| Saccharomyces cerevisiae | 1 | 2017 | 339 | 0.15 | Why? |
| Cryoglobulinemia | 1 | 2017 | 144 | 0.15 | Why? |
| Hyperbaric Oxygenation | 1 | 2019 | 268 | 0.15 | Why? |
| Blood Glucose | 3 | 2019 | 3642 | 0.15 | Why? |
| Metabolic Syndrome | 3 | 2019 | 810 | 0.14 | Why? |
| Carotid Arteries | 1 | 2017 | 182 | 0.14 | Why? |
| MAP Kinase Signaling System | 1 | 2017 | 360 | 0.14 | Why? |
| Diet, Mediterranean | 1 | 2019 | 351 | 0.14 | Why? |
| Diabetes Mellitus | 1 | 2017 | 8207 | 0.14 | Why? |
| Body Mass Index | 2 | 2019 | 4306 | 0.14 | Why? |
| Lung | 3 | 2020 | 31049 | 0.14 | Why? |
| Retrospective Studies | 10 | 2020 | 105322 | 0.14 | Why? |
| Sarcoidosis | 1 | 2018 | 271 | 0.14 | Why? |
| Energy Metabolism | 1 | 2018 | 451 | 0.14 | Why? |
| Risk Factors | 9 | 2021 | 71621 | 0.13 | Why? |
| Autoantibodies | 3 | 2018 | 2094 | 0.13 | Why? |
| Severity of Illness Index | 8 | 2020 | 48226 | 0.13 | Why? |
| Proton Pump Inhibitors | 1 | 2018 | 377 | 0.13 | Why? |
| Expert Testimony | 1 | 2017 | 658 | 0.13 | Why? |
| Pneumonia, Viral | 6 | 2020 | 243684 | 0.13 | Why? |
| Interleukin-17 | 1 | 2018 | 602 | 0.13 | Why? |
| Animals | 8 | 2018 | 78931 | 0.13 | Why? |
| Health Status Indicators | 1 | 2017 | 341 | 0.13 | Why? |
| Predictive Value of Tests | 3 | 2017 | 9537 | 0.13 | Why? |
| Coronavirus Infections | 6 | 2020 | 253789 | 0.13 | Why? |
| Patient Acuity | 1 | 2020 | 1755 | 0.12 | Why? |
| Vitamin D | 2 | 2019 | 2904 | 0.12 | Why? |
| Lymphoma | 1 | 2018 | 522 | 0.12 | Why? |
| Patients | 1 | 2020 | 1167 | 0.12 | Why? |
| Interleukin-10 | 1 | 2019 | 1409 | 0.12 | Why? |
| Antibodies, Monoclonal, Murine-Derived | 1 | 2012 | 94 | 0.12 | Why? |
| Down-Regulation | 1 | 2018 | 1416 | 0.12 | Why? |
| Italy | 8 | 2021 | 38444 | 0.11 | Why? |
| Betacoronavirus | 6 | 2020 | 204454 | 0.11 | Why? |
| Contrast Media | 1 | 2017 | 1011 | 0.11 | Why? |
| T-Lymphocyte Subsets | 1 | 2018 | 1387 | 0.11 | Why? |
| Prevalence | 5 | 2019 | 25773 | 0.10 | Why? |
| Cells, Cultured | 2 | 2018 | 5835 | 0.10 | Why? |
| Vascular Diseases | 1 | 2019 | 846 | 0.10 | Why? |
| Disease Management | 2 | 2019 | 6841 | 0.10 | Why? |
| Respiratory Function Tests | 1 | 2017 | 1755 | 0.10 | Why? |
| Aged | 13 | 2021 | 215776 | 0.10 | Why? |
| Case-Control Studies | 5 | 2020 | 17671 | 0.10 | Why? |
| Skin | 2 | 2018 | 2096 | 0.09 | Why? |
| Lymphocytes | 2 | 2018 | 3056 | 0.09 | Why? |
| Endothelial Cells | 1 | 2019 | 2048 | 0.09 | Why? |
| Prospective Studies | 3 | 2019 | 43301 | 0.09 | Why? |
| Rheumatology | 1 | 2019 | 1213 | 0.09 | Why? |
| Comorbidity | 4 | 2021 | 34796 | 0.08 | Why? |
| Gene Expression Regulation | 1 | 2020 | 4020 | 0.08 | Why? |
| Hypertension | 3 | 2017 | 8895 | 0.08 | Why? |
| Interleukins | 1 | 2012 | 762 | 0.08 | Why? |
| Drug Therapy, Combination | 2 | 2019 | 7268 | 0.08 | Why? |
| Oxygen Inhalation Therapy | 1 | 2020 | 3629 | 0.08 | Why? |
| Adaptive Immunity | 1 | 2018 | 2585 | 0.08 | Why? |
| Seroepidemiologic Studies | 2 | 2019 | 10017 | 0.08 | Why? |
| Antibodies, Antinuclear | 2 | 2018 | 234 | 0.08 | Why? |
| Monocytes | 1 | 2018 | 2978 | 0.08 | Why? |
| Cross-Sectional Studies | 5 | 2021 | 53120 | 0.08 | Why? |
| Guidelines as Topic | 1 | 2018 | 2844 | 0.07 | Why? |
| MicroRNAs | 1 | 2018 | 1787 | 0.07 | Why? |
| B-Lymphocytes | 2 | 2017 | 4418 | 0.07 | Why? |
| Immunoglobulin A | 1 | 2017 | 3567 | 0.07 | Why? |
| Lung Transplantation | 1 | 2017 | 1554 | 0.07 | Why? |
| Genetic Predisposition to Disease | 1 | 2020 | 4027 | 0.07 | Why? |
| Artificial Intelligence | 1 | 2020 | 3543 | 0.07 | Why? |
| Child | 3 | 2020 | 70012 | 0.07 | Why? |
| Psoriasis | 1 | 2019 | 1739 | 0.07 | Why? |
| Ambulatory Care Facilities | 1 | 2016 | 2063 | 0.07 | Why? |
| Pandemics | 7 | 2020 | 389249 | 0.07 | Why? |
| Survival Analysis | 1 | 2018 | 7592 | 0.07 | Why? |
| Quality Improvement | 1 | 2017 | 2435 | 0.07 | Why? |
| Asymptomatic Diseases | 1 | 2017 | 3444 | 0.07 | Why? |
| Leukocytes, Mononuclear | 3 | 2019 | 2115 | 0.07 | Why? |
| Young Adult | 4 | 2018 | 93724 | 0.07 | Why? |
| Vitamin D Deficiency | 1 | 2017 | 1782 | 0.07 | Why? |
| Lung Diseases | 1 | 2017 | 2361 | 0.07 | Why? |
| Longitudinal Studies | 1 | 2019 | 9893 | 0.06 | Why? |
| Fever | 1 | 2020 | 7795 | 0.06 | Why? |
| Hematopoietic Stem Cell Transplantation | 1 | 2017 | 2426 | 0.06 | Why? |
| Cohort Studies | 4 | 2019 | 36005 | 0.06 | Why? |
| CD4-Positive T-Lymphocytes | 1 | 2017 | 4545 | 0.06 | Why? |
| Obesity | 2 | 2019 | 7388 | 0.06 | Why? |
| Quality of Life | 2 | 2019 | 9820 | 0.05 | Why? |
| Ultrasonography | 1 | 2017 | 4409 | 0.05 | Why? |
| Magnetic Resonance Imaging | 1 | 2017 | 6551 | 0.05 | Why? |
| Fertility | 1 | 2004 | 367 | 0.05 | Why? |
| Follow-Up Studies | 1 | 2019 | 17020 | 0.05 | Why? |
| Disease Models, Animal | 1 | 2018 | 10998 | 0.05 | Why? |
| CD59 Antigens | 1 | 2018 | 9 | 0.05 | Why? |
| Age Factors | 2 | 2021 | 21039 | 0.05 | Why? |
| CX3C Chemokine Receptor 1 | 1 | 2018 | 21 | 0.05 | Why? |
| Thyroid Gland | 1 | 2004 | 516 | 0.05 | Why? |
| Anti-Inflammatory Agents | 1 | 2018 | 6153 | 0.05 | Why? |
| Anticoagulants | 1 | 2020 | 9563 | 0.05 | Why? |
| Proto-Oncogene Proteins pp60(c-src) | 1 | 2017 | 1 | 0.05 | Why? |
| Rheumatoid Factor | 1 | 2018 | 67 | 0.05 | Why? |
| Spondylarthritis | 1 | 2021 | 174 | 0.05 | Why? |
| Abortion, Spontaneous | 1 | 2004 | 776 | 0.05 | Why? |
| Interleukin-23 | 1 | 2018 | 64 | 0.05 | Why? |
| Receptors, Interleukin-9 | 1 | 2017 | 1 | 0.05 | Why? |
| Dermis | 1 | 2017 | 35 | 0.04 | Why? |
| Injections | 1 | 2019 | 237 | 0.04 | Why? |
| Anti-Bacterial Agents | 1 | 2020 | 10083 | 0.04 | Why? |
| Smad3 Protein | 1 | 2017 | 40 | 0.04 | Why? |
| Rituximab | 2 | 2019 | 1096 | 0.04 | Why? |
| Extracellular Signal-Regulated MAP Kinases | 1 | 2017 | 92 | 0.04 | Why? |
| Clinical Trials as Topic | 1 | 2017 | 7330 | 0.04 | Why? |
| Receptors, Tumor Necrosis Factor, Type I | 1 | 2018 | 229 | 0.04 | Why? |
| Pneumonia | 1 | 2017 | 5652 | 0.04 | Why? |
| Abatacept | 1 | 2019 | 192 | 0.04 | Why? |
| Rehabilitation Centers | 1 | 2020 | 252 | 0.04 | Why? |
| Peripheral Nervous System Diseases | 1 | 2019 | 193 | 0.04 | Why? |
| Hand | 1 | 2021 | 449 | 0.04 | Why? |
| Cell Hypoxia | 1 | 2017 | 141 | 0.04 | Why? |
| Joints | 1 | 2017 | 97 | 0.04 | Why? |
| Ribonucleoproteins | 1 | 2017 | 151 | 0.04 | Why? |
| Hydroxychloroquine | 1 | 2020 | 12447 | 0.04 | Why? |
| Coculture Techniques | 1 | 2017 | 258 | 0.04 | Why? |
| Trans-Activators | 1 | 2017 | 170 | 0.04 | Why? |
| Interleukin-4 | 1 | 2017 | 367 | 0.04 | Why? |
| Molecular Mimicry | 1 | 2017 | 190 | 0.04 | Why? |
| Biological Factors | 1 | 2019 | 276 | 0.04 | Why? |
| Proto-Oncogene Proteins | 1 | 2017 | 340 | 0.04 | Why? |
| Triglycerides | 1 | 2017 | 478 | 0.03 | Why? |
| Autoantigens | 1 | 2017 | 388 | 0.03 | Why? |
| Germinal Center | 1 | 2017 | 332 | 0.03 | Why? |
| Risk Assessment | 1 | 2018 | 25439 | 0.03 | Why? |
| Central Nervous System Diseases | 1 | 2019 | 410 | 0.03 | Why? |
| Mast Cells | 1 | 2017 | 370 | 0.03 | Why? |
| Time Factors | 1 | 2017 | 31397 | 0.03 | Why? |
| CD4 Lymphocyte Count | 1 | 2019 | 1517 | 0.03 | Why? |
| Observational Studies as Topic | 1 | 2021 | 1887 | 0.03 | Why? |
| Fibroblasts | 1 | 2017 | 839 | 0.03 | Why? |
| Child, Preschool | 1 | 2017 | 36283 | 0.03 | Why? |
| Patient Reported Outcome Measures | 1 | 2019 | 912 | 0.03 | Why? |
| Immunoglobulin G | 1 | 2017 | 21571 | 0.03 | Why? |
| Incidence | 3 | 2021 | 25622 | 0.03 | Why? |
| Th1 Cells | 1 | 2019 | 1228 | 0.03 | Why? |
| Mice, Knockout | 1 | 2017 | 1815 | 0.03 | Why? |
| Immunophenotyping | 1 | 2017 | 1290 | 0.03 | Why? |
| Environment | 1 | 2018 | 769 | 0.03 | Why? |
| Pregnancy Outcome | 1 | 2004 | 3803 | 0.03 | Why? |
| Heparin, Low-Molecular-Weight | 1 | 2020 | 1731 | 0.03 | Why? |
| Drug Combinations | 1 | 2020 | 3852 | 0.03 | Why? |
| Adolescent | 2 | 2017 | 86841 | 0.03 | Why? |
| Enzyme Inhibitors | 1 | 2020 | 1881 | 0.02 | Why? |
| Registries | 2 | 2019 | 12327 | 0.02 | Why? |
| Extracellular Traps | 1 | 2017 | 1036 | 0.02 | Why? |
| Fatigue | 1 | 2019 | 2479 | 0.02 | Why? |
| Antiviral Agents | 1 | 2020 | 41703 | 0.02 | Why? |
| Phenotype | 1 | 2018 | 4037 | 0.02 | Why? |
| Dietary Supplements | 1 | 2019 | 2251 | 0.02 | Why? |
| Mice, Inbred C57BL | 1 | 2017 | 5542 | 0.02 | Why? |
| Patient Care Management | 1 | 2018 | 1514 | 0.02 | Why? |
| Sleep | 1 | 2019 | 2695 | 0.02 | Why? |
| Lopinavir | 1 | 2020 | 4308 | 0.02 | Why? |
| Ritonavir | 1 | 2020 | 4212 | 0.02 | Why? |
| Azithromycin | 1 | 2020 | 3943 | 0.02 | Why? |
| Respiratory System | 1 | 2017 | 3213 | 0.02 | Why? |
| Survival Rate | 1 | 2018 | 9206 | 0.02 | Why? |
| Health Status | 1 | 2017 | 3259 | 0.02 | Why? |
| Internet | 1 | 2021 | 6204 | 0.02 | Why? |
| Symptom Assessment | 1 | 2017 | 4967 | 0.02 | Why? |
| Serologic Tests | 1 | 2017 | 4359 | 0.02 | Why? |
| Surveys and Questionnaires | 2 | 2021 | 43792 | 0.02 | Why? |
| Cell Line | 1 | 2017 | 12040 | 0.01 | Why? |
| Neutrophils | 1 | 2017 | 5476 | 0.01 | Why? |
| Reproducibility of Results | 1 | 2017 | 11304 | 0.01 | Why? |
| Antibodies, Antiphospholipid | 1 | 2004 | 519 | 0.01 | Why? |
| Mice | 1 | 2018 | 21357 | 0.01 | Why? |
| Host-Pathogen Interactions | 1 | 2017 | 11041 | 0.01 | Why? |
| Immunologic Factors | 1 | 2012 | 4206 | 0.01 | Why? |
| United States | 1 | 2021 | 46150 | 0.01 | Why? |
| Aged, 80 and over | 1 | 2017 | 88759 | 0.01 | Why? |
| Pregnancy | 1 | 2004 | 23879 | 0.00 | Why? |